Columbia neuroscientists have identified a genetic mutation that fends off Alzheimer's in people at high risk and could lead to a new way to protect people from the disease.
ADScreen, a speech-processing algorithm developed at Columbia Nursing, is now being tested in a clinical trial to see if it can help health care workers identify patients with Alzheimer's earlier.
Lecanemab, marketed as Leqembi, is the first drug for Alzheimer’s disease to receive approval on the basis of clinically slowing the progression of Alzheimer’s disease.
Attending a high school with a high number of teachers with graduate training was the clearest predictor of the impact of school quality on late-life cognition, researchers found.
Increasingly, transformative therapies are being launched via startups emerging from university research labs, including those at Columbia’s Vagelos College of Physicians and Surgeons.
Scientists initially believed Alzheimer's would be a simple, straightforward problem to solve, but now Columbia researchers are looking for unusual and untried solutions.
Columbia neurologists found that a test used to measure Alzheimer's disease proteins in spinal fluid can be used to determine whether patients have the disease or other forms of dementia.
A newly discovered function for the ApoE4 gene, the strongest genetic risk factor for Alzheimer’s disease, may help explain how the gene causes cognitive decline.
A new clinical trial suggests that donepezil does not improve cognitive performance in people with mild cognitive impairment who also have clinical depression.
In one of the first studies of its kind, Columbia’s Philip De Jager shows how "big data" analyses may lead to new treatment strategies for Alzheimer's disease.